Pre-made Parsatuzumab benchmark antibody ( Whole mAb, anti-EGFL7 therapeutic antibody, Anti-NEU1/VE-STATIN/ZNEU1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Parsatuzumab biosimilar, Whole mAb, Anti-EGFL7 Antibody: Anti-NEU1/VE-STATIN/ZNEU1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFL7.
| Products Name (INN Index) | Pre-Made Parsatuzumab biosimilar, Whole mAb, Anti-EGFL7 Antibody: Anti-NEU1/VE-STATIN/ZNEU1 therapeutic antibody |
|---|---|
| INN Name | Parsatuzumab |
| Target | EGFL7 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Chugai Pharmaceutical,Genentech |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Colorectal cancer,Non-small cell lung cancer,Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | EGFL7 |
| Package |
